Log in

NASDAQ:TMDXTransMedics Group Stock Price, Forecast & News

$15.17
+1.56 (+11.46 %)
(As of 04/9/2020 07:24 AM ET)
Add
Compare
Today's Range
$13.27
Now: $15.17
$15.23
50-Day Range
$10.50
MA: $14.56
$20.07
52-Week Range
$10.10
Now: $15.17
$31.54
Volume138,504 shs
Average Volume151,703 shs
Market Capitalization$321.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TMDX
CUSIPN/A
CIKN/A
Phone978-552-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.60 million
Book Value$2.58 per share

Profitability

Net Income$-33,550,000.00
Net Margins-142.12%

Miscellaneous

EmployeesN/A
Market Cap$321.91 million
Next Earnings Date6/10/2020 (Estimated)
OptionableNot Optionable

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.


TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

How has TransMedics Group's stock been impacted by COVID-19 (Coronavirus)?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TMDX shares have increased by 11.4% and is now trading at $15.17. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TransMedics Group?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TransMedics Group.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for TransMedics Group.

How were TransMedics Group's earnings last quarter?

TransMedics Group Inc (NASDAQ:TMDX) issued its quarterly earnings data on Monday, March, 2nd. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04. The business earned $6.06 million during the quarter, compared to the consensus estimate of $6.51 million. View TransMedics Group's earnings history.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2020 After-Hours earnings guidance on Monday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $40-43 million, compared to the consensus revenue estimate of $46.81 million.

What price target have analysts set for TMDX?

5 brokerages have issued 12-month target prices for TransMedics Group's shares. Their forecasts range from $16.00 to $37.00. On average, they anticipate TransMedics Group's share price to reach $28.00 in the next year. This suggests a possible upside of 84.6% from the stock's current price. View analysts' price targets for TransMedics Group.

Has TransMedics Group been receiving favorable news coverage?

News coverage about TMDX stock has trended very negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. TransMedics Group earned a news impact score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutTransMedics Group.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Gilead Sciences (GILD), Roku (ROKU), AbbVie (ABBV), AT&T (T), Etsy (ETSY), IBM (IBM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Paypal (PYPL) and Zynga (ZNGA).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
  • Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
  • Mr. Brian Thomson, VP of HR (Age 51)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Harbour Capital Advisors LLC (0.12%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr and Tamer I Khayal. View institutional ownership trends for TransMedics Group.

Which institutional investors are buying TransMedics Group stock?

TMDX stock was purchased by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr. View insider buying and selling activity for TransMedics Group.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $15.17.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $321.91 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.  View additional information about TransMedics Group.

What is TransMedics Group's official website?

The official website for TransMedics Group is http://www.transmedics.com/.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel